Subsequent malignancies in children treated for Hodgkin's disease: Associations with gender and radiation dose

被引:84
作者
Constine, Louis S. [1 ,9 ]
Tarbell, Nancy
Hudson, Melissa M. [3 ]
Schwartz, Cindy [5 ]
Fisher, Susan G. [2 ]
Muhs, Ann G. [9 ]
Basu, Swati K. [2 ]
Kun, Larry E. [4 ]
Ng, Andrea [6 ]
Mauch, Peter [6 ]
Sandhu, Ajay
Culakova, Eva [2 ]
Lyman, Gary [7 ]
Mendenhall, Nancy [8 ]
机构
[1] Univ Rochester, Dept Pediat, James P Wilmot Canc Ctr, Rochester, NY 14642 USA
[2] Univ Rochester, James P Wilmot Canc Ctr, Dept Community & Preventat Med, Rochester, NY 14642 USA
[3] St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA
[4] St Jude Childrens Res Hosp, Dept Radiol Sci, Memphis, TN 38105 USA
[5] Johns Hopkins Univ Hosp, Dept Hematol Oncol, Baltimore, MD 21287 USA
[6] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA
[7] Univ Calif San Diego, Ctr Med, San Diego, CA 92103 USA
[8] Univ Florida, Ctr Med, Dept Radiat Oncol, Gainesville, FL USA
[9] Univ Rochester, James P Wilmot Canc Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2008年 / 72卷 / 01期
关键词
pediatric Hodgkin's disease; breast cancer; subsequent malignancy; gender; age;
D O I
10.1016/j.ijrobp.2008.04.067
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Subsequent malignant neoplasms (SMNs) are a dominant cause of morbidity and mortality in children treated for Hodgkin's disease (HD). We evaluated select demographic and therapeutic factors associated with SMNs, specifically gender and radiation dose. Methods and Materials: A total of 930 children treated for HD at five institutions between 1960 and 1990 were studied. Mean age at diagnosis was 13.6 years, and mean follow-up was 16.8 years (maximum, 39.4 years). Treatment included radiation alone (43%), chemotherapy alone (9%), or both (48%). Results: We found that SMNs occurred in 102 (11%) patients, with a 25-year actuarial rate of 19%. With 15,154 patient years of follow-up, only 7.18 cancers were expected (standardized incidence ratio [SIR] = 14.2; absolute excess risk [AER] = 63 cases/10,000 years). The SIR for female subjects, 19.93, was significantly greater than for males, 8.41 (p < 0.0001). After excluding breast cancer, the SIR for female patients was 15.4, still significantly greater than for male patients (p = 0.0012). Increasing radiation dose was associated with an increasing SIR (p = 0.0085). On univariate analysis, an increased risk was associated with female gender, increasing radiation dose, and age at treatment (12-16 years). Using logistic regression, mantle radiation dose increased risk, and this was 2.5-fold for female patients treated with more than 35 Gy primarily because of breast cancer. Conclusions: Survivors of childhood HD are at risk for SMNs, and this risk is greater for female individuals even after accounting for breast cancer. Although SMNs occur in the absence of radiation therapy, the risk increases with RT dose. (C) 2008 Elsevier Inc.
引用
收藏
页码:24 / 33
页数:10
相关论文
共 55 条
  • [1] Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time
    Abrahamsen, AF
    Andersen, A
    Nome, O
    Jacobsen, AB
    Holte, H
    Abrahamsen, JF
    Kvaloy, S
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (11) : 1786 - 1791
  • [2] 2ND MALIGNANCIES AFTER TREATMENT OF HODGKINS-DISEASE - THE INFLUENCE OF TREATMENT, FOLLOW-UP TIME, AND AGE
    ABRAHAMSEN, JF
    ANDERSEN, A
    HANNISDAL, E
    NOME, O
    ABRAHAMSEN, AF
    KVALOY, S
    HOST, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) : 255 - 261
  • [3] [Anonymous], 1999, SEER CANC STAT REV 1
  • [4] Long-term health status among survivors of childhood cancer: Does sex matter?
    Armstrong, Gregory T.
    Sklar, Charles A.
    Hudson, Melissa M.
    Robison, Leslie L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) : 4477 - 4489
  • [5] Risk of selected subsequent carcinomas in survivors of childhood cancer: A report from the childhood cancer survivor study
    Bassal, M
    Mertens, AC
    Taylor, L
    Neglia, JP
    Greffe, BS
    Hammond, S
    Ronckers, CM
    Friedman, DL
    Stovall, M
    Yasui, YY
    Robison, LL
    Meadows, AT
    Kadan-Lottick, NS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 476 - 483
  • [6] SUBSEQUENT MALIGNANCIES IN CHILDREN AND ADOLESCENTS AFTER TREATMENT FOR HODGKINS-DISEASE
    BEATY, O
    HUDSON, MM
    GREENWALD, C
    LUO, XL
    FANG, L
    WILIMAS, JA
    THOMPSON, EI
    KUN, LE
    PRATT, CB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) : 603 - 609
  • [7] High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the late effects study group
    Bhatia, S
    Yasui, Y
    Robison, LL
    Birch, JM
    Bogue, MK
    Diller, L
    DeLaat, C
    Fossati-Bellani, F
    Morgan, E
    Oberlin, O
    Reaman, G
    Ruymann, FB
    Tersak, J
    Meadows, AT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4386 - 4394
  • [8] Breast cancer and other second neoplasms after childhood Hodgkin's disease
    Bhatia, S
    Robison, LL
    Oberlin, O
    Greenberg, M
    Bunin, G
    FossatiBellani, F
    Meadows, AT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (12) : 745 - 751
  • [9] INCIDENCE OF 2ND CANCERS IN PATIENTS TREATED FOR HODGKINS-DISEASE
    BOIVIN, JF
    HUTCHISON, GB
    ZAUBER, AG
    BERNSTEIN, L
    DAVIS, FG
    MICHEL, RP
    ZANKE, B
    TAN, CTC
    FULLER, LM
    MAUCH, P
    ULTMANN, JE
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (10): : 732 - 741
  • [10] ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results
    Bonadonna, G
    Bonfante, V
    Viviani, S
    Di Russo, A
    Villani, F
    Valagussa, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 2835 - 2841